Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Chemotherapy provides symptom relief and extends life in 30-50% of gynecological cancer cases, but has only cured choriocarcinoma.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This case report describes a 22-year-old woman who developed persistent, non-scarring hair loss and premature ovarian failure following a myeloablative umbilical cord transplant for acute myeloid leukemia.

In this retrospective study on pediatric craniospinal irradiation, researchers found that permanent radiation-induced alopecia occurred in 45.8% of patients, with higher radiation doses and treatment intensity being significant predictors, suggesting that defined dosimetric thresholds can support scalp-sparing planning.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

This article reviews drug-induced hair and nail disorders and discusses their clinical recognition, underlying mechanisms, and potential treatment strategies, without presenting new research findings.

This case report describes a 2-month-old infant with a severe seborrhea-like skin eruption and respiratory distress, similar to symptoms that led to a sibling's death from Gram-negative septicemia.

This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.

This article discusses the cutaneous side effects of various chemotherapeutic agents but reports no new clinical results; the authors emphasize the importance of dermatologists recognizing drug-induced skin reactions to better patient care.

The document concludes that while some hair and scalp disorders can be treated, hair loss from destroyed follicles is permanent, and damaged hair can only regrow naturally.

Some drugs can cause hair loss or growth, but hair usually returns to normal after stopping the drug.

This study found that administering chemotherapy to premenopausal women with Stage II breast cancer significantly improved disease-free intervals and increased survival, while postmenopausal women receiving sufficient doses also saw prolonged disease-free periods.

Some chemicals can permanently or temporarily remove color from skin and hair, which can be distressing and is not well-regulated in cosmetics.

Inservice education improves obstetric nursing care and requires teamwork and good planning.

This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.

This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.

This literature study reviews the consequences of hair loss due to chemotherapy and nursing care interventions but reports no new clinical results.

Some drugs can cause hair loss or increase hair growth, but these effects are usually reversible when the drug is stopped.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This review discusses various skin side effects from chemotherapy, noting that they are mainly toxic rather than allergic and often include alopecia, which can cause significant distress to patients.

This review outlines the oral toxic effects of chemotherapy and stresses the need for evaluating dental health prior to treatment to mitigate these complications, but it reports no new clinical results.

This review discusses current knowledge and management strategies for chemotherapy-induced alopecia, highlighting the need for better research prioritization and providing patient support materials, but reports no new clinical results.

This article reviews drug-induced hair changes, highlighting that while many drugs are occasionally linked to hair loss, this connection has been conclusively established for only a few, and such hair loss is typically reversible.

This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.

This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.

This review discusses treatments for chemotherapy-induced alopecia, highlighting scalp cooling for hair loss prevention and 2% topical minoxidil for regrowth acceleration as effective options, but reports a need for more rigorous trials to validate promising new therapies.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalp cooling is the most effective prevention method in most cases, though some questions remain.

This review discusses the causes, clinical presentation, and management of anagen effluvium, emphasizing its psychological impact and the need for empathy and practical support, but reports no new results.

This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.